数据显示，该基金近3个月收益率13.98%，近一年收益率52.72%，成立以来收益率为53.53%。其股票持 仓前十分别为：腾讯控股、美团-W、小米集团-W、中芯国际、德康农牧、赤子城科技、理想汽车-W、 阿里巴巴-W、快手-W、网易-S，前十持仓占比合计52.65%。 截至2025年6月30日，中欧基金旗下中欧港股数字经济混合发起(QDII)C（015885）期末净资产1.30亿 元，比上期减少12.45%，该基金经理为FANG SHENSHEN。 简历显示，FANG SHENSHEN女士:澳大利亚国籍,本科、学士。历任高盛私人财富管理部税务分析 师,Cooper Investors助理基金会计师、交易员、新兴市场组研究员,曾任中欧基金管理有限公司研究员、 高级研究员,现任中欧基金管理有限公司的基金经理。2024年05月31日起担任中欧港股数字经济混合型 发起式证券投资基金(QDII)基金经理。2024年7月1日起任中欧中证港股通央企红利指数发起式证券投资 基金(QDII)的基金经理。2025年01月14日起任中欧恒生科技指数发起式证券投资基金(QDII)基金经理。 近期份额规模变动情况： 日期期间申购（亿 ...

2025 年 07 月 19 日 中欧基金殷姿：高效利用中欧研究 资源，发挥团队优势挖掘阿尔法 ——基金经理研究系列报告之七十五 相关研究 证券分析师 奚佳诚 A0230523070004 xijc@swsresearch.com 蒋辛 A0230521080002 jiangxin@swsresearch.com 邓虎 A0230520070003 denghu@swsresearch.com 联系人 奚佳诚 (8621)23297818× xijc@swsresearch.com 本研究报告仅通过邮件提供给 中庚基金 使用。1 权 益 量 化 研 究 证 券 研 究 报 告 请务必仔细阅读正文之后的各项信息披露与声明 股 票 基 金 - ⚫ 中欧基金殷姿：硕士，历任上海申银万国证券研究所房地产首席分析师，富国基金高级研 究员。2015 年 6 月加入中欧基金，历任研究、权益研究部行政事务负责人及券商管理、权 益研究副总监、权益研究总监，从业年限超 18 年。2024 年 9 月开始管理公募产品，目前 在管 1 只产品——中欧中证 800 研究智选。加入中欧基金后，殷姿的主要工作之一是带教 研究员：中欧基金 ...

来源：金融界 日期期间申购（亿份）期间赎回（亿份）期末总份额（亿份）期末净资产（亿元）净资产变动率2025- 06-300.000.010.020.02-24.80%2025-03-310.000.000.020.02-2.54%2024-12-310.000.020.020.02-47.96%2024- 09-300.000.020.040.04-27.77% 数据显示，该基金近3个月收益率0.38%，近一年收益率1.67%，成立以来收益率为24.96%。 天眼查商业履历信息显示，中欧基金管理有限公司成立于2006年7月，位于上海市，是一家以从事资本 市场服务为主的企业。注册资本22000万人民币，法定代表人为窦玉明。 截至2025年6月30日，中欧基金旗下中欧骏泰货币B（004039）期末净资产197.60亿元，比上期增加 31.52%，该基金经理为张东波。 简历显示，张东波先生:中国国籍,研究生学历、硕士学位。历任东海证券股份有限公司固定收益部债券 交易员(2015.01-2017.02),中山证券有限责任公司资管事业部投资主办助理(2017.02-2017.09)。2017年9月 加入中欧基金管理有限 ...

Group 1 - The fund aims for long-term stable growth of net asset value while controlling investment portfolio risks through tactical asset allocation strategies [2][3] - The fund's performance benchmark is set at 60% of the CSI 300 Index return and 40% of the China Bond Composite Index return [2] - The fund's total share at the end of the reporting period is 1,571,305,662.25 shares [2] Group 2 - The net value growth rate for Class A shares in the past three months is -1.31%, while the benchmark return is 1.28% [5][6] - The net value growth rate for Class C shares in the past three months is -1.43%, with the same benchmark return of 1.28% [5][6] - The fund's investment strategy emphasizes a balanced approach across various sectors and selective stock picking to navigate market challenges [6][7] Group 3 - The fund's asset allocation at the end of the reporting period includes 89.84% in stocks and 5.83% in bonds [8][9] - The top sectors in the fund's investment include manufacturing (33.83%) and finance (31.59%) [9] - The fund has not held any investments in Hong Kong Stock Connect stocks during the reporting period [9]

Group 1 - The core viewpoint of the news is the performance and holdings of the China Europe Medical Health Mixed Fund C, which has shown positive growth in recent months and has a significant allocation in leading healthcare companies [1][3]. - As of July 15, 2025, the latest net value of the fund is 1.7462 yuan, reflecting a growth of 1.28%. The fund's one-month return is 2.18%, six-month return is 18.43%, and year-to-date return is 14.30% [1]. - The fund's top ten stock holdings account for a total of 55.30%, with significant investments in companies such as Heng Rui Pharmaceutical (10.60%), WuXi AppTec (9.95%), and Mindray Medical (5.21%) [1]. Group 2 - The China Europe Medical Health Mixed Fund C was established on September 29, 2016, and as of March 31, 2025, it has a total scale of 15.566 billion yuan. The fund is managed by Guo Lan and Zhao Lei [1]. - Guo Lan, the fund manager, has a background in biomedical engineering and has held various positions in research and fund management since joining China Europe Fund Management in 2014 [2]. - Zhao Lei, also a fund manager, has experience in the pharmaceutical and biotechnology sectors, having worked as a researcher and analyst before joining China Europe Fund Management in 2021 [2].

Group 1 - The fund aims to invest in consumer sectors that enhance the quality of life, with a focus on achieving returns that exceed the performance benchmark while strictly controlling investment risks [2][5] - The fund employs a top-down analysis approach for asset allocation, tracking macroeconomic indicators and policy changes to make strategic investment decisions [2][10] - The fund's performance benchmark is a composite of various indices, including the CSI Major Consumer Industry Index and the Hang Seng Index, reflecting a diversified investment strategy [2][10] Group 2 - During the reporting period from April 1, 2025, to June 30, 2025, the fund's Class A shares achieved a net value growth rate of 4.32%, while Class C shares recorded a growth rate of 4.11% [10] - The fund's investment portfolio is heavily weighted in equities, with stocks accounting for 92.38% of total assets, while bonds represent only 0.18% [12] - The fund's top ten holdings do not include any securities that are under regulatory investigation or have faced public reprimands in the past year [15] Group 3 - The report indicates a stable domestic economic environment, with China's retail sales growth improving to 6.4% in May, up from 3.5% in April, suggesting a positive trend in consumer spending [9] - The A-share market remains active, with major indices showing upward movement, particularly in sectors like defense, beauty care, and light manufacturing [9][10] - The outlook for new consumption trends, particularly in areas like trendy products and beauty care, is optimistic, driven by innovation and changing consumer preferences [10] Group 4 - The fund's total share count at the end of the reporting period was 197,750,306.53 shares, with Class A shares totaling 97,420,757.23 and Class C shares totaling 100,329,549.30 [2][17] - The fund management has adhered to legal regulations and internal policies, ensuring fair trading practices and no instances of unfair trading or profit transfer between different investment portfolios [8][6] - The fund's investment strategy includes a focus on high-growth sectors such as services, brand consumer goods, and technology, indicating a forward-looking approach to capitalizing on market opportunities [10]

Group 1 - The core viewpoint of the news is the performance and holdings of the China Europe Medical Innovation Stock C fund, which has shown a recent decline in net value but strong performance over the past six months and year-to-date [1] - The latest net value of the fund is 1.3561 yuan, reflecting a decrease of 0.74% [1] - The fund's one-month return is -1.63%, ranking 606 out of 673 in its category, while its six-month return is 43.34%, ranking 18 out of 659, and year-to-date return is 36.66%, ranking 22 out of 659 [1] Group 2 - The top ten stock holdings of the China Europe Medical Innovation Stock C fund account for a total of 75.62%, with significant positions in WuXi AppTec (10.35%), Kelun-Biotech (10.15%), WuXi Biologics (9.82%), and others [1] - The fund was established on February 28, 2019, and as of March 31, 2025, it has a total scale of 3.524 billion yuan [1] - The fund manager is Ms. Ge Lan, who has extensive experience in the investment management field, having worked with various funds since joining China Europe Fund Management in 2014 [2]

Group 1 - The core point of the news is the performance and holdings of the China Europe Medical Health Mixed Fund C, which has shown a recent net value increase of 0.94% but a one-month return of -0.94% [1] - The fund's three-month return is 16.34%, ranking 306 out of 1238 similar funds, while its year-to-date return is 10.10%, ranking 434 out of 1218 [1] - The top ten stock holdings of the fund account for a total of 55.30%, with significant positions in companies such as Heng Rui Pharmaceutical (10.60%) and WuXi AppTec (9.95%) [1] Group 2 - The China Europe Medical Health Mixed Fund C was established on September 29, 2016, and as of March 31, 2025, it has a total scale of 15.566 billion yuan [1] - The fund is managed by two key managers: Ms. Ge Lan, who has been managing it since its inception, and Ms. Zhao Lei, who took over management on July 4, 2025 [2]

Group 1 - The core point of the article highlights the recent decline in the stock price of Shenzhen Sinopharm Co., Ltd., which has dropped by 10.47% over five consecutive trading days [1] - Shenzhen Sinopharm Co., Ltd. was established in 1998 and went public in 2009, focusing on an integrated model of research, production, and sales in the pharmaceutical industry [1] - The company's major shareholder, China Europe Fund, reduced its holdings in the first quarter of this year, while the fund has achieved a year-to-date return of 9.28%, ranking 1497 out of 4529 in its category [1][2] Group 2 - The fund managers of China Europe Medical Health Mixed A are Ge Lan and Zhao Lei, with Ge Lan having a background in biomedical engineering and extensive experience in fund management since joining China Europe Fund in 2014 [3][4] - Zhao Lei, who has a master's degree and experience as a research analyst in the pharmaceutical sector, joined China Europe Fund in May 2021 and became a fund manager on July 4, 2025 [5] - China Europe Fund Management Co., Ltd. was established in July 2006 and has a diverse ownership structure, with significant stakes held by various entities including WP Asia Pacific Asset Management LLC and Guodu Securities [5]

Core Insights - In the first half of 2023, 95% of the 6,831 comparable bond funds reported positive performance, with 6,505 funds increasing in value, 29 remaining flat, and 297 declining [1][2] - The top-performing funds included Huashang Fengli Enhanced Regular Open Bond A and C, with returns of 18.35% and 18.11% respectively, primarily investing in convertible bonds [1][2] - Historical data shows that Huashang Fengli Enhanced Regular Open Bond A/C has achieved a cumulative return of over 130% since its inception in September 2016, indicating strong stability [1] Fund Performance - The second tier of funds, such as China Europe Convertible Bond A and Bosheng Convertible Bond Enhanced A, reported gains exceeding 12%, with specific returns of 12.53% and 12.36% respectively [2][3] - The top holdings of these funds predominantly include convertible bonds, with a small allocation to government bonds [2] - The fund managers of these top-performing funds have extensive experience, with some managing public funds for nearly two decades [2][3] Declining Funds - Despite the overall positive market trend, only 9 bond funds experienced declines of over 2%, with the largest drop being 2.47% for the Green Ju Xin Enhanced Bond C, which held no bond assets [3][4] - Other funds that declined include Norde Enhanced Yield Bond, which fell by 2.33%, primarily holding government bonds and a small percentage of stocks [4] - The overall trend indicates a strong bond market performance, with only a few exceptions among the funds [3][4]